World First Use of Lightpoint’s SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain

LONDON, March 27, 2024 (GLOBE NEWSWIRE) — Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a world-first bladder cancer sentinel lymph node (SLN) procedure with SENSEI^®, Telix’s miniature robotic-assisted gamma probe used to detect radiation in patients and guide surgery. The patient was operated on at Hospital del Mar in Barcelona, Spain.

SENSEI® is smaller than an AA battery and designed specifically for robotic-assisted and minimally invasive surgery. The miniature size and proprietary features make the technology ideal for tight surgical spaces such as around the bladder.

With broad application in radio-guided surgery across multiple procedures and major cancer types, SENSEI® is currently indicated for use during SLN biopsy in prostate, endometrial and cervical cancers. As part of an investigator-initiated clinical trial, SENSEI® was used by Dr. Lluís Cecchini with the da Vinci Xi surgical robotic platform in a patient scheduled for radical cystectomy and Bricker urinary diversion with SLN biopsy.

Dr. Lluís Cecchini, Head of Urology at Hospital del Mar said, “Lymph nodes around the bladder have a high chance of being cancerous and are therefore important to excise. Radio-guided surgery has historically been limited by the fact that gamma probes are generally only suitable for open surgery. The size and flexibility of SENSEI® meant it was easy to manipulate within the surgical cavity, see the gamma signal within the robotic console, and quickly locate the SLN, where I might otherwise not have known it was present. Being able to perform the procedure with minimal impact on surrounding healthy tissue is a high surgical priority. With SENSEI® we can deliver a more targeted, focused, and less complex experience for patients.”

Nynke van den Berg, General Manager Medical Technologies (MedTech) at Telix added, “A first bladder cancer procedure with the SENSEI® drop-in gamma probe is a significant milestone for Telix and the Lightpoint team. As we focus on aligning SENSEI® with our Illuccix® and TLX599-CDx programs for prostate cancer, this successful procedure demonstrates the potential and scope to expand use into other urologic malignancies – in line with our portfolio approach to support the patient from diagnosis to surgical intervention and therapy.”

About SENSEI®

Lightpoint has developed SENSEI® – a miniaturised surgical gamma probe for minimally invasive and robot-assisted surgery. The device is approved for sale in the US, EU, UK, and Australia and is in clinical use in the US, UK, Germany, France, Netherlands, Belgium, and Spain.

About Lightpoint

Lightpoint Surgical Ltd (Lightpoint) is an affiliate of Telix Pharmaceuticals Limited. As the MedTech division of Telix, Lightpoint is focused on the development of precision-guided surgical solutions and complementary Artificial Intelligence technologies to aid detection, management and treatment of cancer and rare diseases. Lightpoint is headquartered in the United Kingdom.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Legal Notices

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. The information contained in this announcement is subject to change without notification.

This announcement may contain forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the ASX or on our website.

To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.

©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals, Lightpoint, Illuccix® and SENSEI® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.